Healthcare stocks
Drug makers, biotech, medical devices and healthcare services. People need care in any economy, but drug patents run out, new drugs can fail approval, and governments push prices down.
Stocks1,042
6%
11.1%
26.8×
What drives it
- When a patent ends, cheaper copies take sales away
- A new drug's approval can make or break a small company
- An aging population means steady demand
- How much a company can charge differs a lot by field
Largest companies
By market value, with the same plain verdicts as their stock pages.
| Company | In plain words | |
|---|---|---|
Eli Lilly | $1.20T | |
Johnson & Johnson | $651.1B | |
AbbVie | $505.9B | |
Roche | $382.1B | |
Merck & | $329.7B | |
UnitedHealth | $304.5B | |
Novartis | $284.2B | |
AstraZeneca | $272.1B | |
Thermo Fisher Scientific | $248.1B | |
Amgen | $235.6B | |
Gilead Sciences | $206.4B | |
Abbott Laboratories | $178.4B | |
Novo Nordisk | $166.7B | |
Pfizer | $156.2B | |
Danaher | $155.0B | |
Intuitive Surgical | $138.3B | |
Vertex Pharmaceuticals | $130.6B | |
Medtronic | $127.8B | |
McKesson | $123.5B | |
Bristol-Myers Squibb | $120.2B | |
Stryker | $118.0B | |
Sanofi | $111.7B | |
CVS Health | $103.4B | |
HCA Healthcare | $99.3B | |
GSK | $96.6B | |
Regeneron Pharmaceuticals | $95.2B | |
EssilorLuxottica Société anonyme | $87.8B | |
Waters | $86.6B | |
Elevance Health | $85.2B | |
Moderna | $78.9B |





























